Bulltick Wealth Management LLC Has $2.40 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Bulltick Wealth Management LLC increased its stake in Eli Lilly by 174.8%, holding 2,910 shares valued at approximately $2.4 million after acquiring an additional 1,851 shares this quarter.
• Eli Lilly's stock recently reported a 1.6% increase, with its current market cap at $601.44 billion and significant growth in revenue, up 37.6% year-over-year.
• The company announced a quarterly dividend of $1.50 per share, translating to an annualized dividend of $6.00 and a yield of 0.9%.

Bulltick Wealth Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 174.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,910 shares of the company's stock after purchasing an additional 1,851 shares during the quarter. Bulltick Wealth Management LLC's holdings in Eli Lilly and Company were worth $2,403,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Orion Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.5% during the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after acquiring an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after acquiring an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC grew its stake in shares of Eli Lilly and Company by 212.0% during the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after acquiring an additional 969 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $20.98 during mid-day trading on Wednesday, hitting $660.41. 6,291,111 shares of the company's stock traded hands, compared to its average volume of 5,979,290. The firm has a 50 day simple moving average of $767.52 and a two-hundred day simple moving average of $796.25. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The stock has a market cap of $625.05 billion, a price-to-earnings ratio of 43.16, a P/E/G ratio of 0.90 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm posted $3.92 EPS. The company's quarterly revenue was up 37.6% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Analyst Ratings Changes

LLY has been the subject of several research reports. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Cantor Fitzgerald set a $825.00 price objective on Eli Lilly and Company and gave the company an "overweight" rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $964.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.